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Background
To investigate efficacy and safety of Dialyzed Leukocyte
Extracts (DLE) as adjuvant therapy for moderate atopic
dermatitis (AD).
Design
Double blind, placebo-controlled, randomized, clinical
single-centre trial.
Methods
Fifty-eight paediatric-patients with moderate AD were
enrolled and randomized in two groups: 1) Conventional
treatment (CT) + DLE: Cetirizine (0.25mg/kg), once
daily/4 weeks, Chlorpheniramine (0.35 mg/Kg), daily
divided in 3 doses/4 weeks; and topical Methylpredniso-
lone 0.1%, twice daily/10 days, then once daily/10 days,
and ending every 48h/10 days; plus oral DLE (2mg/5mL),
daily/5 days, then every 72h to complete one month. 2)
CT + placebo, same dosage and administration. Main
outcome measures: Severity of skin lesions evaluated
with SCORAD-Index, and immunophenotypical changes
at day 14, and at end of treatment.
Results
A significant clinical improvement was observed since
day 14 with both, CT and CT + DLE therapy, no significant
differences in the main clinical outcome measures were
found among groups; however a diminished frequency of
CD8+ CD103+ cells, and increased frequency of CLA +
cells, was observed in CT + placebo-group.
Conclusions
Adjuvant therapy with DLE was safe and well-tolerated.
Despite both groups of patients significant improved
after treatment, individuals treated with DLE preserved
cell subsets related to skin immunological regulation,
and avoided systemic expansion of cells related to skin
inflammation.
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